An integrated bioinformatics and multi-omics investigation of the sirtuin family to identify their prognostic importance in human cancers
Background
In recent years, the significance of sirtuins in cancer biology has become increasingly evident, but their molecular mechanisms and prognostic impacts remain elusive.
Objective
The present study aimed to investigate the differential expression of the sirtuin gene family across cancers and to evaluate their prognostic value.
Methods
We used various bioinformatics databases and methodologies, including Oncomine, GEPIA, OncoDB, cBioPortal, R2 Kaplan-Meier Scanner, STRING, etc., to determine the expression pattern of the sirtuin family genes, along with their mutations and prognostic values in human cancers.
Results
In the current study,
SIRT1
,
SIRT2
,
SIRT4
, and
SIRT5
were downregulated in lymphoma, whereas
SIRT6
and
SIRT7
were overexpressed. In breast cancer,
SIRT3
,
SIRT5
, and
SIRT7
were overexpressed, and in terms of kidney cancer, higher expression of
SIRT2
,
SIRT3
, and
SIRT5
was observed. In contrast, for leukemia, bladder, and brain cancers, most sirtuin family members showed reduced expression. We found that most mutations occurred in uterine cancer, chRCC (chromophobe renal cell carcinoma), DLBCL (diffuse large B-cell lymphoma), melanoma, pRCC (papillary renal cell carcinoma), and esophageal cancer. Moreover, we identified the relevant functional proteins through protein-protein interaction analysis to evaluate copy number alterations (CNAs) in sirtuins. The most frequent alterations were amplifications and deep deletions. Survival analysis demonstrated that
SIRT1
and
SIRT2
overexpression correlated with improved overall survival in low-grade glioma but predicted poorer outcomes in ovarian cancer. Downregulation of
SIRT1
,
SIRT3
, and
SIRT5
was associated with better prognosis in DLBCL, while
SIRT3
and
SIRT4
upregulation predicted favorable survival in testicular germ cell tumors.
SIRT6
overexpression was linked to favorable prognosis in esophageal carcinoma and sarcoma, while unfavorable outcomes were observed in hepatocellular carcinoma and cholangiocarcinoma.
SIRT7
upregulation was significantly associated with reduced survival in esophageal, liver, and uterine cancers, but surprisingly correlated with improved outcomes in urothelial carcinoma and cervical squamous cell carcinoma.
Conclusions
Together, this multi-omics analysis reveals the correlation and prognostic values of sirtuins across multiple types of human cancers and suggests that sirtuins may serve as promising biomarkers for different cancers.
